Proteomic breakthrough – the future of blood tests.

Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the publication of a landmark study by a research team from Stanford University School of Medicine.

The publication, titled “Nano-fluidic proteomic assay for serial analysis of oncoprotein activation in clinical samples”, details new methods for detecting small modifications in cancer-related proteins.

Their method allows the use of as little as 4 nanolitres of sample, and is able to measure signalling changes in 25 cells. This would allow repeated smapling to determine cancer regression.

Assuming the technology is transferable to other proteomic applications, we might consider a future nanolitre-scale serum tests for a range of markers!!